Cancer Incidence in Oman 2010

7/30/2019 Cancer Incidence in Oman 2010

1/146

Cancer Incidence in Oman

Report of 2010


2/146


3/146

Cancer Incidence in Oman

Report of 2010

Prepared by

Al i J Mohammed, MDJawad A Al-Lawati, MD

Najla A Al-Lawati, MD

Nabil H Al-Siyabi

Dhahi O Al -Gharbi


4/146

Email : [email protected]


5/146

Preface

I am pleased to foreword the 15th annual report of Cancer Incidence in Oman for the year 2010

coinciding with the meeting of the Council of Health Ministers of the Gulf Cooperation Council.

According to WHO, cancer is a leading cause of death worldwide and accounted for 7.6 million

deaths (around 13% of all deaths) in 2008 and are projected to continue to rise to over 11 million

in 2030. It can be reduced and controlled by implementing evidence-based strategies for cancer

prevention, early detection of cancer and management of patients with cancer. In Oman over the

past few years it ranked as the third leading cause of in-patient mortality.

This report confirms previous findings that cancer is not yet a major public health problem in Oman,

as age adjusted incidence rates in Oman appear to be one of the lowest in comparison to industrial-

ized countries. Although breast cancer incidence is on increase over the past few years, it remains

low compare to other GCC countries, as reported by the recent GCC report publication1. As an

example in Bahrain, the age adjusted incidence rate of breast cancer was reported to be 54.4 per

100,000 population compare to 15.7 in Oman,

I would like to thanks all colleagues working in various institutions for their cooperation in notifying

cancer cases to the National Registry. I hope this report will be able to stimulate the reading of cli-

nician, researcher, administrators and those interested in this filed. We welcome suggestions and

comments on this report in order to improve the quality of cancer registration in Oman.

Dr. Ali Jaffer Mohammed

Chairperson, National Cancer Control Committee

Advisor of Health Af fairs

1Ten Year Cancer Incidence Among Nationals of the GCC States 1998-2007


6/146

Dr. Qasim Al Salmi

Dr. Bassim Al-BahraniDr. Fatima Ramadan

Dr. Zahid Al Mantheri

Dr. Taha Al-Lawati

Dr. Najwa Al Banna

Dr. Eileen Tomas

Dr. Sosamma Thomas

Dr. Usha Sharma

Mr. C.B.Bhat

Mr. Haitham Makki

Mrs.Faiza Al Balushi

Dr. Ali Al Maashani

Dr. Hunain Al-Kindi

Ms. S haika Al-Masoudi

Mr. Fedamani Sathyaseelan

Mr. Saud Al Balushi

Dr. Mohammed Al-Balushi

Dr. Mohammed Issa Al-Ismaili

Mr. Ibrahim Al-Selami

Mr. Essa Al Kalbani

Dr. Adil Al Ansari

Dr. Ali Al-Madhani

Dr. Ashraf fauzi

Dr. Varna Menon

S/N Naima Awadh

Ms. Fatima Rashid

Mr. Sami Al-Baloushi

Mr. Adil Al Khawaldi

Mr. Ouf Khan

Dr. J erard Strong

Mr. Salem Al Shukaily

Mrs. Nadia Al-Salmani

Mr. Essa Al J abri

Dr. Ali Al Adhawi

S/N. Salem Saud Al DhawiMr. Salim Al Harthy

Dr. Mohammed Al-Farsi

Mr. Othman Al-Rasbi

Dr. Mohd. Yahya

Ms. Mariam Al-Araimi

Mrs. Ayesha Al Hashmi

Dr. Salim Al Abri

Dr. Abdul Salaam Abdul Rahman

Dr. Abubaker Al Sadiq

Mr. Hilal Ambusaidi

Dr. J awahir Al Yazidi

Dr. Khalid Al Shihi

Mr.Amer Al Aisry

S/N. Khaleefa Al-Zeedi

Dr. J ohn Idicula

Dr. Ahmed Nada

S/N. Badr Al Hatmi

S/N. Nasser Shanin

Mr. Abdul Rahman Al Hadhrami

Dr. Abdul Rahman Saifudeen

Dr. G. Rajasekharan

Mr. Shanker

S/N.Mariam Saeed Al-Noobi

Dr. J olly Philip

Dr. Imam A.Imam

Mr. Zayed Siyabi

Dr. Ahmed Al Mandhari

Dr. Mansour Al Manthari

Dr. Akram Fawda

Dr. Zakia Al-Lamki

Dr. David Dennison

Dr. Aisha Al Hamadani

Dr. Ibrahim Al Haddabi

Mr. Salim Al Wahaibi

Mr. Saif Al-Raqadi

Mr. Hamed Al Ghaithi

Mr. Leonard brown

Mr. Stuart Donaldson

Mr. Rod Villcrucis

Mr. Yousif Al FalahiMs. Basma Al Raeisi

Ms. Nadheera

Mr. Mohammed Al Maawali

Mr. Mahmood Al Duwaibi

Dr. Aqeed Ali Al Harthi

Dr. Moqaddam Sameer SayyedDr. Raid Masood Al kindi

Mr. Kamal Ahmed

Mr. Al Aqied Sultan Yarub Al-Bus

Dr. Mathew Koshy

Dr. Chakravarthy

Mr. Abdulla Al-Alawi

Dr. Maria Aamir

Ms. J okha Al Rashdi


7/146


8/146

1998-2010

9

99

13

13

13

14

14

14

15

17

22

23

28

29

34

36

40

42

44

46

48

50

52

54

56

58

60


9/146

62

6466

68

70

72

74

76

7881

89

97

100


10/146

8ww.moh.gov.om


11/146

Background

Background Of The Sultanate Of Oman

Geographical FeaturesThe Sultanate of Oman is located in

the southeastern corner of the Arabian

Peninsula. It has a coastal line extending

almost 1,700 kilometers from the Strait

of Hormuz in the north to the borders of

the Republic of Yemen, overlooking three

seas; the Arabian Gulf, Gulf of Oman and

the Arabian Sea. The country bordersSaudi Arabia and United Arab Emirates

(UAE) in the west, the Republic of Yemen

in the south, the Strait of Hormuz in the

north and the Arabian Sea in the east.

Besides, there are a number of scattered

Omani islands in the Arabian Sea; the most

important are Masirah and Al-Halaniyat.

The total area of the Sultanate of Oman is

approximately 309,500 square kilometers

and it is the second largest country in

the Arabian Peninsula. The Sultanate is

composed of varying topographic areas

consisting of plains, wadis (dry river beds)

and mountains. The most important area

is the plain overlooking the Gulf of Oman

and the Arabian Sea with an area of about

3% of the total area. The mountain ranges

occupy almost 15% of the total land of

Oman and are inhabited by about 5% of

the population. The remaining area is

mainly sand, wadis and desert (about 82%

of the total area). The climate differs from

one area to another; it is hot and humid in

the coastal areas in summer, hot and dry

in the interior with the exception of highermountains and Dhofar Governorate, which

enjoy a moderate climate throughout the

year.

The Sultanate of Oman is administratively

divided into 9 Governorates/ Regions with

61 Wilayah. These are: Muscat, Dhofar,

Musandam and Buraimi Governorates

and regions of Ad Dakhliyah, Sharqiyah,

Batinah, Adh Dhahirah, and Al Wusta. The

regions of Sharqiyah and Batinah have

each been further subdivided into two,

for the purpose of health administration,

giving a total of ten health regions.

Population Structure

The estimated mid-year population in 2010

was 2,749,734 of which 1,933,591 were

Omanis and 816,143 were Non-Omanis

(Table 1). The Omani population shows a

sex ratio of 975 females per 1000 males.

About 13.46% of the population is under-5

years and 35.28% is under-15 years. Only

5.17% of the total Omani population is

above the age of 60 years.

Table 2 gives the population distribution

of Omanis by region and gender, which

was used to calculate incidence rates for

different regions.

www.moh.gov.om 9


12/146

Background

Table 1: Age Structure of the Omani Population, 2010

Age Male Female TotalGroup Number % Number % Number %

0 4 132,908 13.58 127,423 13.34 260,331 13.465 9 107,418 10.98 103,849 10.87 211,267 10.9310 14 107,667 11.00 103,056 10.79 210,723 10.9015 19 123,606 12.63 117,382 12.29 240,988 12.4620 24 121,726 12.44 115,848 12.13 237,574 12.2925 29 102,246 10.45 101,433 10.62 203,679 10.5330 34 75,182 7.68 75,806 7.94 150,988 7.8135 39 50,742 5.19 49,461 5.18 100,203 5.18

40 44 36,104 3.69 36,025 3.77 72,129 3.7345 49 28,871 2.95 29,717 3.11 58,588 3.0350 54 24,282 2.48 27,205 2.85 51,487 2.6655 59 16,968 1.73 18,747 1.96 35,715 1.8560 64 16,147 1.65 15,923 1.67 32,070 1.6665 69 11,537 1.18 10,916 1.14 22,453 1.1670 74 11,084 1.13 9,484 0.99 20,568 1.0675 + 12,085 1.24 12,743 1.34 24,828 1.28

Total 978,573 100.00 955,018 100.00 1,933,591 100.00

Table 2: Population Distribution of Omanis by Regions and Gender, 2010

Region Males Females Total

Al Wusta 9,636 9,181 18,817

Ad Dakhliyah 132,818 133,395 265,805

Adh Dhahirah 81,135 78,809 159,944

Dhofar 83,003 79,080 162,083

Musandam 11,272 10,361 21,633

Muscat 206,523 195,543 402,066

North Al Batinah 192,722 189,120 381,842

North Ash Sharqiyah 67,077 67,382 134,459

South Al Batinah 116,876 114,693 231,569

South Ash Sharqiyah 77,511 77,862 155,373

Total 978,573 955,018 1,933,591

www.moh.gov.om 10


13/146

Background

www.moh.gov.om 11

Po

pulationPyramid,Oman,2010

12,74

3

12,085

9,48

4

11,084

10,91

6

11,537

15,92

3

16,147

18,74

7

16,968

27,20

5

24,282

29,71

7

28,871

36,02

5

36,104

49,46

1

50,742

75,80

6

75,182

101,43

3

102,246

115,84

8

121,726

117,38

2

123,606

103,05

6

107,667

103,84

9

107,418

127,42

3

132,908

978,573

955,0

18


14/146

Background

Health Administrative Regions of The Sultanate of Oman

This diagram is not an authority on international boundaries

Administrative boundaries for Al-Buraimi not shown.

www.moh.gov.om 12


15/146

Registry Methods

Oman National Cancer Registry

The Oman National Cancer Registry was

established in 1985 as a hospital based

registry. Only cases treated in tertiary

hospitals were registered. In 1996, with the

establishment of the Department of Non-

Communicable Diseases Surveillance

and Control, the cancer registry was

transferred and started functioning under

the Directorate General of Health Affairs.

New cancer notification forms were

developed and distributed to all regionalhospitals and sister institutions. In the year

2000, the registration form was simplified

(see annex 2), printed and distributed to

all institutions that could potentially report

cancer cases. Two trained cancer registrars

are responsible for data collection, coding

and data entry.

Objective of Cancer Regist ry

1. To compile an accurate database on the

incident cases of cancer inThe Sultanate

of Oman.

2.To monitor the trends of cancer which

can guide policy makers in setting priorities

for control and management of cancer.

3.To provide researchers and clinicians

with population based information on the

number and types of cancer cases and

their geographical distribution within theSultanate of Oman

Methods

1. Data Collection

a) Active Collection

Active collection involves the registry

personnel visiting different sources and

abstracting data on Cancer Registry

Forms. Being the largest tertiary centre

for diagnosis and treatment of cancer,

registrars visit the Royal Hospital twice a

week and abstract data on the notification

forms. Similarly, other tertiary hospitals like

Khoula Hospital and Al-Nahda Hospital are

visited once a month.

A new National Oncology Centre was

established in the Royal Hospital inNovember 2004 after which data is also

collected in the form of chemotherapy and

radiotherapy lists.

Patients diagnosed abroad are traced

through the Oncology Outpatient Register

at the Royal Hospital and subsequently

data are extracted from their case notes.

Details of patients treated abroad are

obtained from the Department of Treatment

Abroad, Ministry of Health.

b) Passive Reporting

Cancer notification was made mandatory

in the year 2001 through a Ministerial

Decision (4/2001). When a case of cancer

is diagnosed, the attending physician

of the relevant specialty or the medicalrecords department at the regional hospital

completes the notification forms and sends

them to the registry. Other institutions like

the Armed Forces Hospital and Sultan

Qaboos University Hospital do similar

passive reporting.

www.moh.gov.om 13


16/146

Registry Methods

2. Data-Coding, Entry and Validity

Checks

Until 2001 all cancer cases were beingcoded using International Classification ofDiseases for Oncology (ICDO-2) codes,2nd Edition, with topography C andmorphology M codes. Data was enteredin CanReg-3 programme, supplied bythe International Agency for Research onCancer (IARC), Lyon, France. Canreg-4software programme and InternationalClassification of Diseases for OncologyICDO-3 began to be used from 2003, sinceit was introduced in October 2002. Thisprogramme has a duplicate entry checkingfacility, which avoids the same case beingregistered more than once. For this reportwe used Canreg-4.28. Validity checks areperformed for consistency between items:site/histology, gender/site and age/site/histology combinationsby Canreg-4.28.

3. Completeness of Data Report ing

1.Firstly, data are obtained from all hospitalswith pathology/ hematology laboratories(Royal, al-Nahdha, Khoula, Salalah andSohar Hospitals) by way of copies ofreports of patients diagnosed as cancer tothe registry. Since the middle of 2001, theSultan Qaboos University laboratory hasalso started sending reports.

2. Secondly, since the establishment of

the new National Oncology Center inNovember 2004, the chemotherapy andradiotherapy lists are also obtained oncea week.

3. Thirdly, monthly hospital admission discharge lists are being sent from thetertiary hospitals. . From this year, similarlists are being sent by all the regionalhospitals as well. These lists help inupdating the registry as well as in updating

the status of the patient (expired or alive).

4. Fourthly, the list of cancer patientscoming for chemotherapy to the tertiaryhospital is obtained.

5. Further, the Diwan of Royal Court sendsabroad certain patients who cannot betreated in Oman. With the co-operationof the Diwan of Royal Court, this list ofpatients is also obtained since 2002.

6. Some Omani patients living near theborder go to Tuwam Hospital in the UnitedArab Emirates (a country bordering Oman)for diagnosis and management of cancer.A list of these patients is also obtainedannually.

Details of missing data are sought from allthese above sources so that the registrycan be updated.

4.Data Analysis

Data is first checked for consistency andvalidity using the International Agency forResearch on Cancer (IARC), 1998 software(Canreg-4.28). Frequency distribution andincidence tables are generated using theCanreg-4 programme. Data for individualcancers are then exported to the EPIINFOversion 6 (Centre for Disease Control andPrevention, Georgia, Atlanta, USA) for

analysis of incidence by region, genderand morphological types. The results forchildhood cancers are presented for thewhole Sultanate according to the diagnosticgroups defined in the InternationalClassification of Childhood Cancers, thirdedition, 2005 Steliarova-Foucher et al.,2005). Bar diagrams and graphs weremade using Microsoft excel.

www.moh.gov.om 14


17/146

Registry Methods

Oman National Cancer Registry

5. Definitions

Incidence

is the number of new cancer cases in a

defined population within a specific period.

Date of Diagnosis

is the date documented on the histopathol-

ogy report. For clinical cases, the date of

diagnosis is the date stated in patientscase notes to have cancer.

Population at Risk

The part of the Omani population that is

susceptible to have a specific cancer.

Crude incidence rate

Is the number of new cancer cases in

the Omani population occurring within a

Gregorian calendar (1st J anuary to 31st

December) divided by the population at

risk in the same period expressed per

100,000.

Age-specific rate

Incidence rate in a specific age group.

Multiple primariesTwo or more abnormal growths of tissue

occurring simultaneously. The neoplasms

are histologically different and may be

found in the same or different sites.

Metastasis

Metastasis is the distant spread of cancer

from its original site to other organs of the

body, including lymph nodes, skeletal and

or visceral organs.

www.moh.gov.om 15


18/146

Registry Methods

Age-standardized rate (ASR) Table 3 : Age Structure of the World

Standard population of Segi,used for

Age - adjustmentAge standardization is necessary when

comparing several populations that dif-Age Group Population

fer with respect to age. Hence the World00-04 12,000

Standard Population of Segi, (Table 3)05-09 10,000

(Segi M. Cancer mortality for selected sites10-14 9,000

in 24 countries (1950-57). Sendai: Tohuku15-19 9,000

University, School of Medicine, 1960) was20-24 8,000

used to adjust the crude incidence rates25-29 8,000

and to remove the confounding effect of30-34 6,000

age. Therefore, the age-adjusted rates35-39 6,000

(ASR) given in tables 8 and 9 could be 40-44 6,000used for comparison purposes with other45-49 6,000

rates where the same world standard pop-50-54 5,000

ulation was used, especially those issued55-59 4,000

by the World Health Organizations agen-60-64 4,000

cy, the International Agency for Research65-69 3,000

on Cancer (IARC), in its periodic publica-70-74 2,000

tion Cancer Incidence in Five Continents.75+ 2,000

Total 100,000

Table 4 : Stability of data overtime

Incidence Year

Publ. Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

1999 847

2000 866 883

2001 882 895 892

2002 888 905 892 783

2003 889 905 913 787 841

2004 889 906 917 805 867 895

2005 890 909 920 821 870 911 876

2006 891 910 923 824 872 926 906 847

2007 891 910 924 827 881 927 920 848 837

2008 891 910 931 831 881 939 937 882 899 881

2009 891 910 934 831 881 940 937 883 900 899 915

2010 891 910 934 831 940 940 937 883 900 901 921 876

Max 891 910 934 831 881 940 937 883 900 901 921

Min 847 883 892 783 841 895 876 847 837 881 915

Average 882 823.3 817.1 813.6 870.4 923 915.2 865 878.6 891 918

Max-Min 44 27 42 48 40 45 61 36 63 20 6

Max variation % 5% 3.28% 5.10% 5.89% 5.10% 4.59% 6.6% 4.16% 7.2% 2.20% 0.65%

The table shows the total number of registrations annually and the updated numbers for each year following publication.

www.moh.gov.om 16


19/146

17ww.moh.gov.om

Trends of cancer

1998 - 2010


20/146

Trends of cancer

Table 5: Frequency o f Cancers among Omanis, 1998-2010, Males

Site 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Lip 2 2 2 2 1 0 2 1 2 0 1 0 1Tongue 1 5 6 4 3 4 4 4 6 5 4 3 2

Mouth 6 5 3 2 7 4 10 7 2 5 6 8 3

Salivary glands 6 0 1 1 2 1 5 0 0 1 2 1 1

Tonsi l 0 1 0 1 0 0 1 1 2 2 1 0 1

Other Oroph arynx 0 0 2 0 0 3 3 3 2 0 1 0 1

Nasophary nx 4 2 8 7 3 3 7 4 2 4 5 6 4

Hypoph arynx 1 2 1 1 4 1 8 0 0 0 1 3 0

Pharynx unsp ec. 0 0 0 0 0 1 1 0 0 1 0 1 0

Oesophagu s 10 10 10 11 12 9 9 12 11 9 5 7 13

Stom ach 50 56 56 56 54 35 34 53 42 35 31 45 27

Small int estine 1 1 1 2 3 0 0 2 0 2 0 2 1

Colo n 15 6 13 12 12 13 17 22 21 20 17 22 29

Rectu m 9 9 6 13 8 14 6 17 14 11 9 17 9

Anu s 1 4 1 5 4 3 2 1 1 2 2 1 0

Liver 31 35 27 30 13 21 26 34 18 19 30 18 15

Gallbladder etc. 2 3 5 2 3 3 3 7 2 7 3 3 5

Pancreas 5 6 10 13 2 6 12 7 6 5 8 10 11

Nose, sinuses etc. 1 3 2 0 0 2 5 2 3 3 1 1 1

Larynx 10 5 5 2 2 7 8 9 10 6 4 4 11

Trachea,Bronchus,Lung 32 49 37 44 30 30 31 30 30 41 28 28 19

Other Thoraci c organs 1 1 3 3 1 1 2 1 3 2 1 3 0

Bon e 6 5 4 3 6 7 10 10 1 5 4 9 12

Melanoma of Skin 1 0 1 4 2 1 4 1 0 2 2 3 2

Other Skin 22 13 15 18 27 19 19 17 17 22 22 25 21

Mesothel ioma 1 2 1 1 0 1 0 0 1 1 1 0 0

Kaposi sarcoma 0 5 1 2 7 4 0 2 4 3 2 2 2

Connect ive,Soft tis sue 11 6 14 8 7 7 13 6 4 3 9 5 12

Breast 3 3 3 6 5 5 3 7 6 4 1 5 7

Penis 0 0 0 0 0 0 0 1 0 0 1 0 1

Prostate 40 45 37 45 32 30 26 40 27 51 38 43 41

Testis 4 3 1 5 5 5 7 3 6 5 7 5 4

Other male genit al 0 0 0 0 0 0 1 0 0 0 1 1 0

Kidney 5 8 13 6 6 15 6 12 6 4 5 13 15

Renal Pelv is 0 0 1 0 0 0 0 0 0 2 0 0 0

Ureter 0 0 0 1 0 0 0 0 1 0 0 0 0

Bladder 23 26 17 19 19 20 19 27 27 28 24 25 32

Other Urinary organs 1 1 1 0 1 0 0 0 2 0 0 0 0

Eye 5 3 2 2 0 4 5 4 2 5 1 1 0

Brain , Nervous system 25 15 18 29 17 21 27 17 10 13 14 22 16

Thyroid 5 8 5 14 11 15 8 10 5 7 9 10 2Adr enal g land 0 1 1 1 0 3 2 2 3 1 0 3 4

Other Endoc rine 0 1 0 1 0 0 1 0 1 1 0 1 0

Hodg kin disease 21 18 18 21 18 19 22 12 20 11 16 12 12

Non-Hodgk in lymphom a 38 43 43 38 37 50 49 43 41 40 40 36 35

Immun oproli ferati ve dis. 1 0 0 0 0 0 0 0 0 0 1 0 0

Multi ple Myeloma 8 7 10 9 6 3 9 12 4 9 8 7 8

Lymph oid Leukaemia 19 20 18 20 22 23 28 20 17 10 26 25 16

Myeloid Leukaemia 14 11 14 14 12 22 10 14 20 20 16 11 13

Leukaemia unsp ec. 5 4 4 7 12 6 6 3 1 5 2 1 6

Other & unspecified 30 24 29 24 27 21 27 19 21 24 19 21 8

Al l s ites Total 476 477 470 509 444 464 498 499 425 456 429 469 423

Al l s ites bu t C44 454 464 455 491 417 445 479 482 408 434 407 444 402

www.moh.gov.om 18


21/146

Trends of cancer

Table 6: Frequency o f Cancers among Omanis, 1998-2010, Females

Site 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Lip 1 0 0 0 0 1 2 0 1 1 2 0 0

Tongue 0 4 2 0 1 2 2 1 1 2 2 2 3

Mouth 1 4 2 2 1 3 3 2 1 5 3 5 3

Salivary glands 2 2 1 2 0 7 4 1 4 2 1 2 2

Tonsi l 0 0 0 0 0 0 0 0 0 0 0 0 0

Other Oroph arynx 0 0 0 0 0 2 1 2 0 1 0 0 0

Nasophary nx 1 4 2 0 5 4 2 0 1 1 4 2 3

Hypoph arynx 2 1 1 2 1 2 1 0 3 1 1 0 0

Pharynx unsp ec. 0 0 0 1 0 0 0 0 0 1 1 0 0

Oesophagus 13 12 9 7 5 4 4 5 6 10 6 8 5

Stom ach 30 26 22 20 30 19 30 33 27 18 15 23 23

Small int estine 1 0 0 3 2 0 2 1 1 0 2 1 1

Colo n 13 3 11 10 9 13 12 15 13 20 21 20 11

Rectu m 9 0 8 7 9 11 8 6 12 12 9 11 15

Anu s 0 0 1 0 1 2 1 2 2 3 1 1 2

Liver 13 16 13 11 8 8 6 9 11 4 5 16 14

Gallbladder etc. 4 5 3 6 2 2 3 4 6 4 6 5 1

Pancreas 8 5 5 7 3 3 7 8 4 1 7 4 3

Nose, sinuses etc. 2 0 1 1 4 1 0 2 0 2 0 4 0

Larynx 2 0 2 2 2 1 1 1 2 1 0 3 1

Trachea,Bronchus,Lung 7 8 8 13 5 9 10 9 13 6 11 14 6

Other Thoraci c organs 0 1 0 0 0 2 0 1 0 2 2 0 1

Bon e 3 7 4 2 3 5 5 4 7 2 3 1 3

Melanoma of Skin 1 1 4 0 1 1 2 0 1 3 2 2 2

Other Skin 12 24 20 14 7 11 10 17 14 8 15 19 23

Mesothel ioma 0 0 1 0 0 0 0 0 0 0 0 0 0

Kaposi sarcoma 1 4 2 0 1 3 0 0 0 1 2 1 1

Connect ive,Soft tis sue 4 5 10 4 7 2 10 6 6 5 5 1 3

Breast 58 58 74 77 74 63 95 95 97 105 106 105 115

Vulva 0 1 1 1 1 4 3 0 3 2 0 0 1

Vagina 2 0 3 1 2 0 2 1 4 0 2 0 0

Cervi x Uter i 29 25 32 24 17 34 30 25 29 23 28 11 35

Corpus Uteri 4 1 3 6 7 8 10 7 8 10 12 12 13

Uterus unsp ec. 6 6 0 6 3 2 3 1 2 3 6 2 2

Ovary 31 31 26 23 19 17 14 25 23 23 20 13 15

Other Female Genital 0 0 0 0 1 0 1 0 2 3 0 0 0

Placen ta 0 0 5 2 0 1 1 0 1 1 0 1 0

Kidney 8 4 11 11 6 10 3 10 4 6 16 8 9

Renal Pelvis 0 0 0 0 0 0 0 1 0 0 0 0 0

Ureter 0 0 0 1 0 0 0 1 0 0 0 0 0

Bladder 8 12 6 9 12 8 11 9 15 8 9 9 8

Other Urinary organs 0 0 0 0 0 0 0 0 0 1 0 0 0

Eye 4 5 2 1 2 2 2 3 1 3 1 1 2

Brain , Nervous system 18 17 13 19 9 8 21 10 13 11 13 11 14Thyroid 36 35 26 41 35 36 30 34 38 37 36 49 33

Adrenal g land 2 1 3 3 1 3 1 0 3 0 4 1 0

Other Endoc rine 0 0 0 1 0 0 0 0 0 0 0 0 0

Hodgki n disease 5 9 14 5 11 11 5 8 5 9 12 10 11

Non-Hodgkin lymphoma 19 19 29 27 23 31 33 26 22 27 29 30 32

Immunoproli ferati ve dis . 0 0 0 0 . 0 . 0 0 . 0 . 0 0 0 0 0

Mult iple Myeloma 6 9 10 2 1 6 6 5 7 3 3 6 6

Lympho id Leukaemia 13 9 11 14 11 12 12 14 11 10 21 9 10

Myeloid Leukaemia 7 9 15 11 7 11 9 7 9 10 14 13 14

Leukaemia unsp ec. 3 5 4 8 11 11 4 2 2 7 3 3 0

Other & unspecified 34 25 19 17 27 21 22 25 23 26 11 13 7

Al l s ites Total 423 413 440 425 387 417 442 438 458 444 472 452 453

406 432 421 444 436 457 433 430Al l s ites bu t C44 411 389 420 411 380

www.moh.gov.om 19


22/146

Trends of cancer

Table 7: Age-adjusted Incidence Rates in Omanis, 1998-2010, Males

Site 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Lip 0.7 0.7 0.5 0.4 0.2 0 0.8 0.3 0.5 0 0.1 0 0.3Tongue 0.3 1.2 1.3 0.9 0.7 0.9 0.8 1 1.5 1.3 1.2 0.7 0.3

Mouth 1.6 1 0.8 0.4 1.5 0.9 3 1.9 0.3 1.1 1.3 1.7 0.7

Salivary glands 1.3 0 0.2 0.3 0.5 0.1 1.5 0 0 0.1 0.3 0.2 0.2

Tonsi l 0 0.2 0 0.3 0 0 0.3 0.2 0.5 0.6 0.2 0 0.2

Other Oroph arynx 0 0 0.5 0 0 0.7 0.8 0.8 0.4 0 0.3 0 0.2

Nasopharynx 0.8 0.4 1.5 1.3 0.3 0.4 0.7 1 0.6 0.9 1.3 1.1 0.7

Hypo pharynx 0.2 0.4 0.2 0.1 0.7 0.2 1.9 0 0 0 0.3 0.7 0

Pharynx unsp ec. 0 0 0 0 0 0.3 0.3 0 0 0.3 0 0.2 0

Oesophagu s 2.6 2.6 2.4 2.6 2.8 2.1 3.1 3.5 3.2 2.6 1.3 1.9 2.9

Stom ach 13.5 14 12.9 13.2 12 7.8 10.6 16 13 9.7 8.1 11.8 5.4

Small int estine 0.2 0.3 0.2 0.4 0.6 0 0 0.4 0 0.5 0 0.5 0.3

Colo n 3.5 1.5 3 2.4 2.7 2.9 4.3 5.5 5.2 5 3.9 4.8 5.2

Rectu m 2.5 1.8 1.1 3 1.6 3.1 1.6 4.5 3.7 3 2.2 4.2 1.7Anu s 0.2 0.9 0.3 1.2 0.8 0.7 0.6 0.3 0.3 0.5 0.5 0.2 0

Liver 7.8 9.5 6.1 6.8 3 5 8 9.8 4.5 4.5 8 4.5 3.1

Gallbladder etc. 0.5 0.8 1.2 0.5 0.7 0.7 1.1 2.3 0.5 1.8 0.9 0.7 1.1

Pancreas 1.3 1.7 2.3 3 0.5 1.4 4.1 2.3 1.9 1.2 2.3 2.3 2.4

Nose, sinuses etc . 0.2 0.7 0.5 0 0 0.1 0.8 0.6 0.5 0.9 0.1 0.2 0.2

Lary nx 2.7 1.3 1.2 0.4 0.4 1.7 2.6 2.6 2.5 1.3 1.1 0.8 2.3

Trachea,Bronchus,Lung 8.4 12.9 8.8 10 6.8 6.9 9.6 8.3 8.2 11.6 7.5 7.3 4.2

Other Thoraci c organs 0.2 0.2 0.6 0.5 0.2 0.1 0.4 0.1 0.6 0.3 0.1 0.7 0

Bon e 1.1 0.8 0.7 0.2 0.7 0.9 1.3 0.9 0.3 0.5 0.3 0.7 1.3

Melano ma of Skin 0.3 0 0.2 1 0.4 0.3 1.1 0.3 0 0.3 0.5 0.5 0.3

Other Skin 5.8 3.1 3.4 4 5.4 4.1 5.3 5.4 5.1 5.9 5.4 6.2 4.4

Mesothel ioma 0.4 0.4 0.2 0.2 0 0.3 0 0 0.3 0.3 0.3 0 0

Kapo si sarcom a 0 1.3 0.2 0.5 1.2 0.7 0 0.5 0.7 0.5 0.5 0.5 0.3

Connect ive,Soft tis sue 1.6 1 2 1.3 0.9 1.3 1.7 0.8 0.6 0.4 1.4 0.7 1.8

Breast 0.6 0.7 0.7 1.4 0.8 1.1 0.7 1.7 1.8 0.9 0.1 1.4 1.5

Penis 0 0 0 0 0 0 0 0.2 0 0 0.3 0 0.2

Prostate 11.1 12 9 10.6 7.4 6.9 8.5 12.3 8.2 15.2 11.4 12 8.5

Testis 0.5 0.5 0.2 0.7 0.9 0.6 1 0.5 0.7 0.4 0.7 0.4 0.3

Other male genit al 0 0 0 0 0 0 0.2 0 0 0 0.1 0.1 0

Kidney 1.3 1.6 2.5 1.2 1.1 2.6 1.7 2.2 1.2 1.1 1.5 3.2 2.7

Renal Pelv is 0 0 0 0 0 0 0 0 0 0.7 0 0 0

Ureter 0 0 0 0.3 0 0 0 0 0.3 0 0 0 0

Bladder 5.8 6.6 3.8 4.4 4.1 4.8 5.2 7.3 7.5 7.6 6.7 6.7 6.7

Other Urinary organs 0.2 0.3 0.1 0 0.2 0 0 0 0.6 0 0 0 0

Eye 0.8 0.6 0.3 0.3 0 0.8 0.9 1 0.5 1.1 0.2 0.1 0

Brain , Nervous system 3.6 2.8 3 4.4 3.2 3.2 4.1 2.8 1.5 2.3 1.8 3.1 2

Thyroid 1.3 1.7 1.1 2.8 1.6 3.2 1.6 2 0.8 1.4 1.6 1.5 0.4

Adr enal g land 0 0.1 0.2 0.1 0 0.3 0.2 0.2 0.4 0.1 0 0.3 0.5

Other Endoc rine 0 0.1 0 0.2 0 0 0.3 0 0.1 0.1 0 0.1 0

Hodg kin disease 3.6 2.2 2.7 3 2.4 2.5 2.8 2 2.2 1.6 2.8 1.4 1.5

Non-Hodgk in lymphoma 9 9 7.9 7.3 7.1 9.7 10.6 9 7.8 6.9 8.9 6.5 6

Immunoproli ferati ve dis. 0.2 0 0 0 0 0 0 0 0 0 0.3 0 0

Multiple Myeloma 2 1.6 2.4 2.1 1.4 0.8 3.1 3.5 1.2 2.6 2.2 1.9 1.3

Lymphoid Leukaemia 1.9 2.6 2.5 2.6 2.4 3.3 3.5 2.2 2.5 1.3 2.5 3 1.7

Myelo id Leukaemi a 2.8 2.2 2.9 1.8 1.9 3.1 1.9 2.6 3.5 3.8 3.2 1.5 1.7

Leukaemia unspec . 0.6 0.6 0.6 1.2 1.2 1.1 0.6 0.4 0.1 0.4 0.2 0.3 0.8

Other & unspecified 7.8 5.2 6.8 5 5.3 4.2 7.6 4.6 5.8 5.6 4.8 5 1.7

Al l s ites Total 110.9 109.1 99.2 104.3 85.4 92.3 120.4 124.2 101.3 108.5 98.4 101.3 76.8

Al l s ites bu t C44 105.1 106 95.8 100.3 80 88.2 115.1 118.7 96.2 102.6 93 95.1 72.4

www.moh.gov.om 20


23/146

Trends of cancer

Table 8: Age-adjusted Incidence Rates in Omanis, 1998-2010, Females

Site 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Lip 0.4 0 0 0 0 0.2 0.2 0 0.3 0.4 0.5 0 0Tongue 0 0.9 0.5 0 0.1 0.4 0.3 0.2 0.4 0.5 0.3 0.3 0.3

Mouth 0.2 1 0.4 0.4 0.1 0.7 0.6 0.6 0.3 1.3 0.8 1.5 0.2

Salivary glands 0.5 0.4 0.2 0.3 0 1.2 0.8 0.4 0.7 0.4 0.1 0.3 0.1

Tonsi l 0 0 0 0 0 0 0 0 0 0 0 0 0

Other Oroph arynx 0 0 0 0 0 0.6 0.3 0.7 0 0.3 0 0 0

Nasopharynx 0.2 0.8 0.2 0 0.6 0.7 0.1 0 0.2 0.2 1 0.4 0.2

Hypo pharynx 0.4 0.4 0.2 0.4 0.2 0.5 0.5 0 0.7 0.3 0.3 00 0

Pharynx unsp ec. 0 0 0 0.3 0 0 0 0 0 0.1 0.3 00 0

Oesophagu s 4.4 3.3 2.1 1.7 1.1 0.9 1.5 1.9 2 3.1 1.7 2.4 0.5

Stom ach 8.2 7 5.6 4.4 6.8 4 9.7 10.1 6.8 5.1 4.1 5.8 2.3

Small int estine 0.3 0 0 0.7 0.5 0 0.6 0.4 0.3 0 0.6 0.3 0.1

Colo n 3.1 1 2.4 2.4 2.1 2.4 3.4 3.4 3 4.7 4.3 4.2 0.9

Rectu m 2.1 0 2 1.5 2.2 2.6 1.9 1.2 2.7 2.6 1.9 2.4 1.5

Anu s 0 0 0.2 0 0.1 0.5 0.4 0.7 0.5 0.6 0.3 0.3 0.2Liver 3.3 4.1 3.1 2.5 1.7 1.9 1.9 2.2 2.4 1.2 1.7 3.8 1.5

Gallbladder etc. 1.1 1.4 0.8 1.4 0.3 0.5 1.2 1.1 1.8 1.3 1.5 1.1 0.1

Pancreas 2.4 1.2 1.2 1.8 0.7 0.8 2.7 2 1 0.3 1.6 1 0.3

Nose, sinuses etc. 0.5 0 0.3 0.1 0.8 0.3 0 0.4 0 0.3 0 1.1 0.0

Lary nx 0.4 0 0.4 0.5 0.4 0.3 0.2 0.2 0.8 0.3 0 0.8 0.1

Trachea,Bronchus,Lung 1.6 2.1 2 3.2 1 2.2 3.1 2.4 3.6 1.6 3 3.4 0.7

Other Thoraci c organs 0 0.1 0 0 0 0.3 0 0.1 0 0.4 0.5 0 0.0

Bon e 0.2 0.6 0.4 0.4 0.2 0.3 0.8 0.7 0.8 0.1 0.4 0.1 0.2

Melano ma of Skin 0.2 0.1 0.9 0 0.1 0.2 0.5 0 0.1 0.5 0.5 0.4 0.2

Other Skin 3.1 5.5 4.8 3.3 1.5 2.5 3.7 4 4.1 2.1 4.7 4.8 2.2

Mesothel ioma 0 0 0.2 0 0 0 0 0 0 0 0 0 0

Kaposi sarcoma 0.2 0.9 0.4 0 0.2 0.6 0 0 0 0.2 0.7 0.4 0.1

Connect ive,Soft tis sue 0.3 1.1 1.5 0.7 1 0.3 1.4 0.7 0.8 0.7 0.7 0.1 0.1

Breast 13.4 13.8 15.6 16 14.8 13.6 22.9 21.8 22.6 22.1 22 19.9 9.7

Vulva 0 0.4 0.3 0.3 0.2 0.8 1 0 1 0.3 0 0 0.1

Vagina 0.6 0 0.6 0.2 0.5 0 0.4 0.1 1.5 0 0.8 0 0.0

Cervi x Uter i 7.2 6.3 7.3 5.7 3.8 7.6 7.6 7.4 6.4 5.7 6.6 2.3 3.4

Corpus Uter i 0.9 0.2 0.8 1.5 1.8 1.7 3.1 2.2 2.2 2.8 2.9 3.2 1.3

Uterus uns pec. 1.3 1.8 0 1.4 0.7 0.6 0.6 0.4 0.5 0.8 1.6 0.4 0.2

Ovary 7.8 7 5.8 4.5 3.7 3.6 3.1 5.3 4.9 5.5 3.4 2.4 1.2

Other Female Genital 0 0 0 0 0.2 0 0.1 0 0.5 0.8 0 0 0

Placen ta 0 0 0.8 0.3 0 0.1 0.1 0 0.2 0.1 0 0.2 0.0

Kidney 1.7 1 1.8 2 0.7 2.2 0.6 1.8 0.8 1.2 3.7 1.7 0.7

Renal Pelvis 0 0 0 0 0 0 0 0.3 0 0 0 0 0

Ureter 0 0 0 0.2 0 0 0 0.3 0 0 0 0 0

Bladder 1.6 3.4 1.5 2.1 2.8 2 3.6 2.9 4.8 2.1 2.5 1.8 0.7

Other Urinary organs 0 0 0 0 0 0 0 0 0 0.2 0 0 0

Eye 0.8 0.9 0.2 0.2 0.3 0.2 0.2 0.5 0.3 0.4 0.2 0.3 0.2

Brain , Nervous system 3 2.4 1.9 3.2 1.1 1.2 2.5 1.4 2.2 1.7 1.7 1.3 1.0

Thyroid 6.8 5.9 4.2 7 6.1 5.9 4.8 6.4 6.3 5.6 4.6 6.4 2.2

Adr enal g land 0.3 0.2 0.5 0.3 0.1 0.3 0.1 0 0.3 0 0.4 0.1 0.0

Other Endoc rine 0 0 0 0.1 0 0 0 0 0 0 0 0 0

Hodg kin disease 0.5 2 1.9 0.7 1.3 1.6 0.6 1.7 0.7 1.5 1.8 1.8 0.6

Non-Hodgk in lymphoma 3.8 3.3 5.4 5.1 4.5 5.2 8.7 6 4.5 6 5.5 5.7 3

Immunoproli ferati ve dis. 0 0 0 0 0 0 0 0 0 0 0 0 0

Multi ple Myeloma 1.9 2.5 2.7 0.5 0.2 1.5 1.9 1.5 2.3 0.8 0.9 1.6 0.7

Lymphoid Leukaemia 2.1 1 1.3 1.7 1.3 1.7 2 1.8 1.9 1 2.4 1 0.5

Myeloid Leukaemia 1 1.9 2.5 1.8 0.9 2.1 1.8 1.3 1.3 1.5 2.1 2.1 1

Leukaemia unspec . 0.6 0.4 0.7 1.2 1.6 1.8 0.7 0.1 0.2 1.2 0.5 0.5 0.0

Other & unspecified 8.9 6.6 4.5 3.6 5.5 4.4 6.2 6.5 6.6 6.9 2.6 2.6 0.6

Al l s ites Total 97.6 92.7 90.3 85.9 73.6 82.7 108.8 103.3 105.3 97.1 97.8 90.2 38.9

Al l s ites bu t C44 94.5 87.2 85.5 82.6 72.1 80.3 105.1 99.3 101.2 95.1 93.1 85.3 36.7

www.moh.gov.om 21


24/146

Overall Results

Overall ResultsTable 9. : Distribution of Cancer Cases in Oman by Nationality

Nationality Frequency Percentage (%)

Omanis 876 92.31

Non-Omanis 73 7.69

Total 949 100

The male : female ratio was 0.93 :1. 60 cases (6.8%) were reported in children aged 14 years and

below. The median age at diagnosis was 53 years. This was higher in males (median age 57

years) than in females (median age 50 years).

Table 10 : Distr ibut ion of Cancer Cases Among Omanis by Gender

Gender Frequency Percentage (%)

Male 423 48.29

Female 453 51.71

Total 876 100

www.moh.gov.om 22


25/146

Figure

2:Age-Specifi

cincidenc

eratesbygender,2010

Overall Results

Incidence rate (per 100,000)

800

700

600

500

400

300

200

100

0

23www.moh.gov.om

0-9

10-19

20-29

30-39

40-49

50-59

60-69

Agegroup

(years)


26/146

Overall Results

Table 11: Frequency of Incident Cases in Omani Males , 2010

SITE ALL AGE 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+ % of ICDAGES UNK. -4 -9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 -69 -74 Total (10th)

Lip 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0.20% C00

Tongue 2 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0.50% C01-C02

Mouth 3 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0.70% C03-C06

Salivary glan ds 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0.20% C07-C08

Tonsi l 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0.20% C09

Other Orophary nx 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0.20% C10

Nasop hary nx 4 0 0 0 0 0 1 0 0 0 1 0 1 0 0 1 0 0 0.90% C11

Hypoph arynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C12-C13

Phary nx unspec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C14

Oesop hagus 13 0 0 0 0 0 0 0 0 0 0 0 0 0 5 3 1 4 3.10% C15

Stomach 27 0 0 0 0 0 0 0 0 3 2 1 4 1 5 4 3 4 6.40% C16

Small int esti ne 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0.20% C17

Colon 29 0 0 1 0 0 2 2 1 3 1 4 4 3 0 6 0 2 6.90% C18

Rectum 9 0 0 0 0 0 0 1 0 0 1 2 1 1 1 0 1 1 2.10% C19-C20

Anus 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C21

Liv er 15 0 2 0 0 0 0 0 0 0 1 0 2 4 3 1 1 1 3.50% C22

Gallb ladder etc. 5 0 0 0 0 0 0 0 0 0 0 0 1 2 1 0 1 0 1.20% C23-C24

Pancreas 11 0 0 0 0 0 0 0 0 0 2 1 2 1 2 2 1 0 2.60% C25

Nose, sin uses etc. 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0.20% C30-C31

Lary nx 11 0 0 0 0 0 0 0 0 0 2 0 3 3 1 0 2 0 2.60% C32

Trachea,Bronchu s,Lung 19 0 0 0 0 0 0 0 0 0 1 2 0 4 5 2 3 2 4.50% C33-C34

Other Thoracic organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C37-C38

Bone 12 0 0 0 3 3 3 1 0 0 0 0 0 0 1 1 0 0 2.80% C40-C41

Melanoma of Skin 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0.50% C43

Other Skin 21 0 0 0 0 0 0 0 0 0 1 1 0 5 4 1 6 3 5.00% C44

Mesotheli oma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C45

Kaposi sarcoma 2 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0.50% C46

Connect ive,Soft tissue 12 0 1 0 1 1 1 2 0 0 0 0 1 0 1 2 1 1 2.80% C47;C49

Breas t 7 0 0 0 0 0 0 0 0 0 1 1 0 1 2 0 1 1 1.70% C50

Penis 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0.20% C60

Pros tate 41 0 0 0 0 0 0 0 0 1 0 0 1 3 7 8 12 9 9.70% C61

Testis 4 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0.90% C62

Other male geni tal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C63

Kidney 15 0 2 0 0 0 0 0 1 1 1 2 2 0 1 3 0 2 3.50% C64

Renal Pelvi s 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C65

Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C66

Bladder 32 0 0 0 0 0 0 0 0 1 1 2 5 2 6 4 7 4 7.60% C67

Other Urinary organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C68

Eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C69

Brain, Nervous sys tem 16 0 4 1 1 1 1 1 0 2 0 2 0 0 1 0 1 1 3.80% C70-C72

Thyr oid 2 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0.50% C73

Adrenal g land 4 0 2 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0.90% C74

Other Endocr ine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C75

Hodgki n disease 12 0 0 0 1 2 2 0 1 3 0 0 1 1 0 1 0 0 2.80% C81

Non-Hodgk in lymphoma 35 0 0 4 0 0 2 1 3 1 2 5 3 5 1 3 4 1 8.30% C82-C85;C96

Immunop roli ferative dis. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C88

Mult ipl e Myeloma 8 0 0 0 0 0 0 2 0 0 1 1 1 1 0 0 0 2 1.90% C90

Lympho id Leuk aemia 16 0 3 3 1 2 2 1 1 0 1 0 0 0 1 0 1 0 3.80% C91

Myelo id Leuk aemia 13 0 2 1 0 0 0 1 2 2 1 1 1 0 0 0 0 2 3.10% C92-C94

Leukaemia unsp ec. 6 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 1 1 1.40% C95

Other & unspecified 8 0 1 0 0 0 0 0 0 0 1 0 0 2 3 0 1 0 1.90% Other

All sit es Total 423 0 18 10 8 10 17 14 10 18 21 31 34 43 54 44 49 42 100.00% All

All sit es bu t C44 402 0 18 10 8 10 17 14 10 18 20 30 34 38 50 43 43 39 95.00% Not C44

www.moh.gov.om 24


27/146

Overall Results

Table 12: Frequency of Incident Cases in Omani Females, 2010

SITE ALL AGE 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+ % of ICDAGES UNK. -4 -9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 -69 -74 Total (10th)

Lip 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C00

Tongue 3 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0.70% C01-C02

Mout h 3 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0.70% C03-C06

Salivary glands 2 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0.40% C07-C08

Tonsi l 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C09

Other Orophary nx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C10

Nasopharynx 3 0 0 0 0 0 0 0 1 2 0 0 0 0 0 0 0 0 0.70% C11

Hypo phar ynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C12-C13

Pharynx uns pec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C14

Oesop hagus 5 0 0 0 0 0 0 0 0 0 0 0 2 2 1 0 0 0 1.10% C15

Stomach 23 0 0 0 0 0 1 0 0 1 2 1 2 3 4 2 4 3 5.10% C16

Small int esti ne 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0.20% C17

Colon 11 0 0 0 0 0 0 2 1 1 2 0 1 1 1 1 1 0 2.40% C18

Rectum 15 0 0 0 0 0 0 0 1 0 3 2 1 6 2 0 2 0 3.30% C19-C20

Anus 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0.40% C21

Liv er 14 0 0 0 0 0 0 0 0 0 1 4 1 2 3 0 2 1 3.10% C22

Gallb ladder etc. 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0.20% C23-C24

Pancreas 3 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0.70% C25

Nose, sinus es etc. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C30-C31

Lary nx 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0.20% C32

Trachea,Bronchus,Lung 6 0 0 0 0 0 0 0 0 1 0 0 0 1 3 1 0 0 1.30% C33-C34

Other Thoracic organs 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.20% C37-C38

Bone 3 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0.70% C40-C41

Melanoma of Skin 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0.40% C43

Other Skin 23 0 0 0 0 2 0 1 0 2 1 0 2 3 2 5 0 5 5.10% C44

Mesot heli oma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C45

Kaposi sarc oma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0.20% C46

Connecti ve,Soft tissue 3 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0.70% C47;C49Breas t 115 0 0 0 0 0 0 0 15 10 09 18 21 9 6 5 5 8 25.40% C50

Vulva 1 0 0 0 0 0 0 9 0 0 0 0 0 1 0 0 0 0 0.20% C51

Vagina 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C52

Cervi x Uteri 35 0 0 0 0 0 0 2 2 2 5 2 4 8 4 4 0 2 7.70% C53

Corpus Uteri 13 0 0 0 0 0 0 0 2 0 0 1 1 3 2 2 2 0 2.90% C54

Uterus uns pec. 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0.40% C55

Ovary 15 0 0 0 0 0 2 3 2 0 0 0 0 3 2 1 0 1 3.30% C56

Other Female Genit al 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C57

Placen ta 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C58

Kidney 9 0 1 0 0 0 2 1 0 0 0 2 1 0 1 0 1 0 2.00% C64

Renal Pelvi s 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C65

Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C66

Bladder 8 0 0 0 0 0 0 1 1 0 1 1 0 1 1 0 1 1 1.80% C67

Other Urinary organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C68

Eye 2 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0.40% C69

Brain, Nervous syst em 14 0 3 0 1 0 0 1 2 0 1 1 2 0 1 1 0 1 3.10% C70-C72

Thyr oid 33 0 0 0 0 0 2 3 10 4 5 1 4 0 1 2 1 0 7.30% C73

Adrenal g land 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C74

Other Endocri ne 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C75

Hodg kin dis ease 11 0 0 1 2 1 2 0 1 2 0 2 0 0 0 0 0 0 2.40% C81

Non-Hodgk in lymphoma 32 0 0 0 0 4 0 2 0 0 3 2 3 3 6 3 2 4 7.10% C82-C85;C96

Immunop roli ferative dis. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C88

Mult ipl e Myeloma 6 0 0 0 0 0 0 0 0 0 0 0 2 1 2 1 0 0 1.30% C90

Lymphoid Leukaemia 10 0 3 2 3 0 1 0 0 0 0 0 0 0 0 0 1 0 2.20% C91

Myelo id Leuk aemia 14 0 1 0 0 1 1 2 1 0 2 0 1 0 0 2 1 2 3.10% C92-C94

Leukaemia uns pec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% C95

Other & unspecified 7 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 2 1 1.50% Other

All sit es Total 453 0 12 4 8 8 11 29 40 27 39 37 51 49 44 32 30 32 100.00% All

All sit es bu t C44 430 0 12 4 8 6 11 28 40 25 38 37 49 46 42 27 30 27 94.90% Not C44

www.moh.gov.om 25


28/146

Overall Results

Table 13: Age-specifc Incidence Rates among Omani Males, 2010

SITE ALL AGE 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+ CRUDE ASR ICD

AGES UNK. -4 -9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 -69 -74 RATE World (10th)

Lip 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8.7 0 0 0.1 0.3 C00

Tongue 2 0 0 0 0 0 0 0 0 2 0 3.5 0 0 0 0 0 0 0.2 0.3 C01-C02

Mouth 3 0 0 0 0 0 0 0 0 0 0 3.5 0 5.9 6.2 0 0 0 0.3 0.7 C03-C06

Salivary glands 1 0 0 0 0 0 0 0 0 0 0 3.5 0 0 0 0 0 0 0.1 0.2 C07-C08

Tonsi l 1 0 0 0 0 0 0 0 0 0 0 3.5 0 0 0 0 0 0 0.1 0.2 C09

Other Oropharynx 1 0 0 0 0 0 0 0 0 0 0 0 0 5.9 0 0 0 0 0.1 0.2 C10

Nasop hary nx 4 0 0 0 0 0 0.8 0 0 0 2.8 0 4.1 0 0 8.7 0 0 0.4 0.7 C11

Hypoph arynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 C12-C13

Pharynx unspec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 C14

Oesop hagus 13 0 0 0 0 0 0 0 0 0 0 0 0 0 31 26 9 33.1 1.3 2.9 C15

Stomac h 27 0 0 0 0 0 0 0 0 5.9 5.5 3.5 16.5 5.9 31 34.7 27.1 33.1 2.8 5.4 C16

Small int esti ne 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8.7 0 0 0.1 0.3 C17

Colon 29 0 0 0.9 0 0 1.6 2 1.3 5.9 2.8 13.9 16.5 17.7 0 52 0 16.6 3 5.2 C18

Rectum 9 0 0 0 0 0 0 1 0 0 2.8 6.9 4.1 5.9 6.2 0 9 8.3 0.9 1.7 C19-C20

Anus 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 C21

Liv er 15 0 1.5 0 0 0 0 0 0 0 2.8 0 8.2 23.6 18.6 8.7 9 8.3 1.5 3.1 C22

Gallb ladder etc. 5 0 0 0 0 0 0 0 0 0 0 0 4.1 11.8 6.2 0 9 0 0.5 1.1 C23-C24

Pancreas 11 0 0 0 0 0 0 0 0 0 5.5 3.5 8.2 5.9 12.4 17.3 9 0 1.1 2.4 C25

Nose, sin uses etc. 1 0 0 0 0 0 0 0 0 0 0 3.5 0 0 0 0 0 0 0.1 0.2 C30-C31

Lary nx 11 0 0 0 0 0 0 0 0 0 5.5 0 12.4 17.7 6.2 0 18.1 0 1.1 2.3 C32

Trachea,Bronchus,Lung 19 0 0 0 0 0 0 0 0 0 2.8 6.9 0 23.6 31 17.3 27.1 16.6 1.9 4.2 C33-C34

Other Thoracic organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 C37-C38

Bone 12 0 0 0 2.8 2.4 2.5 1 0 0 0 0 0 0 6.2 8.7 0 0 1.2 1.3 C40-C41

Melanoma of Skin 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 8.3 0.2 0.3 C43

Other Skin 21 0 0 0 0 0 0 0 0 0 2.8 3.5 0 29.5 24.8 8.7 54.2 24.8 2.1 4.4 C44

Mesotheli oma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C45

Kaposi sarc oma 2 0 0 0 0 0 0.8 0 0 0 0 0 0 5.9 0 0 0 0 0.2 0.3 C46

Conn ecti ve,Sof t tis sue 12 0 0.8 0 0.9 0.8 0.8 2 0 0 0 0 4.1 0 6.2 17.3 9 8.3 1.2 1.8 C47- C49

Breas t 7 0 0 0 0 0 0 0 0 0 2.8 3.5 0 5.9 12.4 0 9 8.3 0.7 1.5 C50

Penis 1 0 0 0 0 0 0 0 0 0 0 0 0 0 6.2 0 0 0 0.1 0.2 C60

Pros tate 41 0 0 0 0 0 0 0 0 2 0 0 4.1 17.7 43.4 69.4 108.3 74.5 4.2 8.5 C61

Testis 4 0 0.8 0 0 0 0.8 1 1.3 0 0 0 0 0 0 0 0 0 0.4 0.3 C62

Other male geni tal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C63

Kidney 15 0 1.5 0 0 0 0 0 1.3 2 2.8 6.9 8.2 0 6.2 26 0 16.6 1.5 2.7 C64

Renal Pelvi s 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C65

Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C66

Bladder 32 0 0 0 0 0 0 0 0 2 2.8 6.9 20.6 11.8 37.2 34.7 63.2 33.1 3.3 6.7 C67

Other Urinary organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C68

Eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C69

Brai n, Nervous system 16 0 3 0.9 0.9 0.8 0.8 1 0 3.9 0 6.9 0 0 6.2 0 9 8.3 1.6 2.0 C70-C72

Thyroid 2 0 0 0 0 0 0 0 0 0 0 3.5 0 5.9 0 0 0 0 0.2 0.4 C73

Adrenal g land 4 0 1.5 0 0 0 0 0 0 0 0 0 4.1 0 0 0 0 0 0.4 0.5 C74

Other Endocr ine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C75

Hodgkin dis ease 12 0 0 0 0.9 1.6 1.6 0 1.3 5.9 0 0 4.1 5.9 0 8.7 0 0 1.2 1.5 C81

Non-Hodgkin lymphoma 35 0 0 3.7 0 0 1.6 1 4 2 5.5 17.3 12.4 29.5 6.2 2.6 36.1 8.3 3.6 6.0 C82-C85

Immunoproliferative dis. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C88

Mult ipl e Myeloma 8 0 0 0 0 0 0 0 0 0 2.8 3.5 4.1 5.9 0 0 0 16.6 0.8 1.3 C90

Lympho id Leuk aemia 16 0 2.3 2.8 0.9 0.6 1.6 0 1.3 0 2.8 0 0 0 6.2 0 9 0 1.6 1.7 C91

Myelo id Leuk aemia 13 0 1.5 0.9 0 0 0 1 2.7 3.9 2.8 3.5 4.1 0 0 0 0 16.6 1.3 1.7 C92-C94

Leukaemia uns pec. 6 0 0 0 0.9 0.8 0.8 0 0 0 0 0 0 0 6.2 0 9 8.3 0.6 0.8 C95

Other & unspecified 8 0 0.8 0 0 0 0 0 0 0 2.8 0 0 11.8 18.6 0 9 0 0.8 1.7 Other

All si tes Total 423 0 14 9 7 8 14 14 13 35 58 107 140 254 335 382 442 348 43.3 76.8 All

All si tes but C44 402 0 14 9 7 8 14 14 13 35 55 104 140 224 310 373 388 323 41.1 72.4 Not C44

www.moh.gov.om 26


29/146

Overall Results

Table 14: Age-specifc Incidence Rates among Omani Females, 2010

SITE ALL AGE 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+ CRUDE ASR ICD

AGES UNK. -4 -9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 -69 -74 RATE World (10th)

Lip 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C00

Tongue 3 0 0 0 0 0 0 0 0.7 0 0 0 1.9 0 0 4.5 0 0 0.2 0.3 C01-C02

Mout h 3 0 0 0 0 0 0 0 0 0 1.4 0 0 0 0 0 0 8.1 0.2 0.2 C03-C06

Salivary glands 2 0 0 0 0 0 0 0.5 0 0 1.4 0 0 0 0 0 0 0 0.1 0.1 C07-C08

Tonsi l 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C09

Other Oroph arynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C10

Nasopharynx 3 0 0 0 0 0 0 0 0.7 2 0 0 0 0 0 0 0 0 0.2 0.2 C11

Hypopharynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C12-C13

Pharynx unsp ec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C14

Oesophagus 5 0 0 0 0 0 0 0 0 0 0 0 3.9 5.6 3.1 0 0 0 0.3 0.5 C15

Stomach 23 0 0 0 0 0 0.4 0 0 1 2.8 1.7 3.9 8.4 12.5 8.9 19.5 12.1 1.2 2.3 C16

Small int estin e 1 0 0 0 0 0 0 0 0 0 0 1.7 0 0 0 0 0 0 0.1 0.1 C17

Colon 11 0 0 0 0 0 0 1 0.7 1 2.8 0 1.9 2.8 3.1 4.5 4.9 0 0.6 0.9 C18

Rectum 15 0 0 0 0 0 0 0 0.7 0 4.2 0 1.9 16.8 6.2 0 9.7 0 0.8 1.5 C19-C20

Anus 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.9 4 0.1 0.2 C21

Liver 14 0 0 0 0 0 0 0 0 0 1.4 6.8 1.9 5.6 9.4 0 9.7 4 0.7 1.5 C22

Gallbl adder etc. 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.9 0 0.1 0.1 C23-C24

Pancreas 3 0 0 0 0 0 0 0 0 0 0 0 0 5.6 0 0 4.9 0 0.2 0.3 C25

Nose, sinuses etc. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C30-C31

Laryn x 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0.1 0.1 C32

Trachea,Br onchus,L ung 6 0 0 0 0 0 0 0 0 1 0 0 0 2.8 9.4 4.4 0 0 0.3 0.7 C33-C34

Other Thorac ic organs 1 0 0.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.1 0.0 C37-C38

Bon e 3 0 0 0.5 0.5 0 0 0 0 0 1.4 0 0 0 0 0 0 0 0.2 0.2 C40-C41

Melanoma of Skin 2 0 0 0 0 0 0 0.5 0 0 0 0 0 0 0 4.5 0 0 0.1 0.2 C43

Other Skin 23 0 0 0 0 0.8 0 0.5 0 2 1.4 0 3.9 3.4 6.2 22.3 24.3 20.2 1.2 2.2 C44

Mesotheliom a 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C45

Kapos i sarco ma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 0 0 0 0.1 0.1 C46

Connect ive,Sof t tis sue 3 0 0.8 0 0.5 0 0 0 0 0 0 0 0 0 0 0 0 0 0.2 0.1 C47;C49

Breast 115 0 0 0 0 0 0 4.4 9.9 10 12.5 30.7 40.8 25.2 18.7 22.3 24.3 32.2 6 9.7 C50

Vulva 1 0 0 0 0 0 0 0 0 0 0 0 0 2.8 0 0 0 0 0.1 0.1 C51

Vagina 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C52

Cervix Uteri 35 0 0 0 0 0 0 1 1.3 2 6.9 3.4 7.8 22.4 12.5 17.8 0 8.1 1.8 3.4 C53

Corpus Uteri 13 0 0 0 0 0 0 0 1.3 0 0 1.7 1.9 8.4 6.2 8.9 9.7 0 0.7 1.3 C54

Uterus unsp ec. 2 0 0 0 0 0 0 0 0 0 0 0 1.9 0 0 0 4.9 0 0.1 0.2 C55

Ovary 15 0 0 0 0 0 0.8 1.5 1.3 0 0 0 0 8.4 6.2 4.5 4.9 0 0.8 1.2 C56

Other Female Genital 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C57

Placenta 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C58

Kidn ey 9 0 0.4 0 0 0 0.8 0.5 0 0 0 3.4 1.9 0 3.1 0 4.9 4 0.5 0.7 C64

Renal Pelvis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C65

Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C66

Bladder 8 0 0 0 0 0 0 0.5 0.7 0 1.4 1.7 0 2.8 3.1 0 4.9 4 0.4 0.7 C67

Other Urinary organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C68

Eye 2 0 0.4 0 0 0 0 0 0 0 0 0 0 0 3.1 0 0 0 0.1 0.2 C69

Brain , Nervous sys tem 14 0 1.2 0 0.5 0 0 0.5 1.3 0 1.4 1.7 3.9 0 3.1 4.5 0 4 0.7 1.0 C70-C72

Thyroid 33 0 0 0 0 0 0.8 1.5 6.6 4 6.9 1.7 7.8 0 3.1 8.9 4.9 0 1.7 2.2 C73

Adrenal gland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C74

Other Endoc rine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C75

Hodgk in disease 11 0 0 0.5 0.9 0.4 0.8 0 0.7 2 0 3.4 0 0 0 0 0 0 0.6 0.6 C81

Non-Hodgkin lymp homa 32 0 0 0 0 1.7 0 1 0 0 4.2 3.4 5.8 8.4 18.7 13.4 9.7 16.1 1.7 3 C82-C85;C96

Immun opro liferativ e dis . 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C88

Multi ple Myeloma 6 0 0 0 0 0 0 0 0 0 0 0 3.9 2.8 6.2 4.5 0 0 0.3 0.7 C90

Lymp hoid Leukaemia 10 0 1.2 0.9 1.4 0 0.4 0 0 0 0 0 0 0 0 0 4.9 0 0.5 0.5 C91

Myeloid Leukaemia 14 0 0.4 0 0 0.4 0.4 1 0.7 0 2.8 0 1.9 0 0 8.9 4.9 8.1 0.7 1 C92-C94

Leukaemia unspec. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 C95

Other & unspecified 7 0 0 0 0 0 0 0 0 1 1.4 1.7 1.9 0 0 0 9.7 4 0.4 0.6 Other

All sit es Tot al 453 0 5 2 4 3 5 14 27 27 54 63 99 137 137 143 146 129 23.4 38.9 All

All sit es bu t C44 430 0 5 2 4 2 5 14 27 25 53 63 95 129 131 120 146 109 22.3 36.7 Not C44

www.moh.gov.om 27


30/146

Overall Results

Table 15: Incident Cases by most valid basis of diagnosis among Omanis, 2010

Site A* B* C* D* Total

Lip 0 0 1 0 1

Tongue 0 0 5 0 5

Mouth 0 0 6 0 6

Salivary Glands 0 0 4 0 4

Oropharynx 0 0 1 0 1

Nasophary nx 0 0 7 0 7

Hypopharynx 0 0 0 0 0

Oesophagus 0 0 18 0 18

Stomach 0 1 49 0 50

Colon 0 1 39 0 40

Small intest ine 0 0 2 0 2

Rectum 0 0 24 0 24

Liver 0 0 29 0 29

Gall Bladder 0 0 6 0 6

Pancreas 0 0 14 0 14

Nose, Sinuses 0 0 1 0 1

Larynx 0 0 12 0 12

Trachea, Bronchus , Lung 0 1 24 0 25

Bone 0 0 15 0 15

Connecti ve tiss ue 0 0 15 0 15

Melanoma 0 0 4 0 4

Skin 0 1 43 0 44

Kaposi s sarcom a 0 0 3 0 3

Breast 0 1 121 0 122

Cervix uteri 0 0 35 0 35

Uterus Unspecified 0 0 15 0 15

Ovary 0 2 13 0 15

Other female genital 0 0 0 0 0

Prostate 0 0 41 0 41

Testis 0 0 4 0 4

Kidney 0 0 24 0 24

Bladder 0 0 40 0 40

Eye 0 0 2 0 2

Brain, Nervous System 0 0 27 2 29

Thyroi d 0 0 35 0 35

Hodgki ns Disease 0 0 23 0 23

Non Hodgki ns Disease 0 0 67 0 67

Plasmacyto ma 0 0 14 0 14Leukemia 0 0 59 0 59

Other and Unspecified 0 0 25 0 25

Total 0 7 867 2 876

Percentage of total 0 0.80 98.97 0.23 100

*Key to basis of diagnosis

A =Death certificate only

B =Non-microscopic: clinical, clinical investigation, and specific tumour markers, exploratory surgery

without histology

C =Microscopic: cytology, histology of primary, and histology of metastasis

D =Unknown

www.moh.gov.om 28


31/146

Overall Results

Common Cancers in Omanis

Table 16: Ten Most Common Cancers among Omanis (Males & Females)

Topography Frequency

Breast 122*

Non-Hodgkin Lymphoma 67

Leukemia 59

Stomach 50

Other skin 44

Prostate 41

Bladder 40

Colon 40

Thyroid 35

Brain 30

* includes 7 cases of male breast cancer

Figure 3: Most Common Cancers in Oman

4.5%

3.8%

Lung/Bronchus

6.4% 5.1%Stomach

6.9%

3.6%

Colon

Kidney

5.0% Skin, others 5.1%

7.3%

3.3%

3.3%7.7%

3.3%

5.3%

7.1%8.3% Non-HodgkinLymphoma

8.3% Leukemia

Ovary

Cervix

Rectum

7.6% Bladder

9.7% Prostate

Uterus

Thyroid

Brain

Breast 25.4%

www.moh.gov.om 29


32/146

Figure

4:

Frequency

distri

bu

tiono

fthe

tenmos

tcomm

oncancersamong

Oman

is

(ma

lesan

dfema

les

),2010

(Frequency)

122

67

59

50

44

41

40

40

35

30

Breas

t

Non-Hodgkin

Leu

kem

ia

Stoma

ch

Others

kin

Pros

tate

Bladder

Co

lon

Thyro

id

Brain

Lymphoma

Overall Results

www.moh.gov.om 30


33/146

Overall Results in Oman and GCC Comparison

Overall Results

Table 17: Ten Most Common Cancer among Omani Males and Females 2010

Male Female

Topography Frequency Percentage (%) Topography Frequency Percentage (%)

Prostate 41 9.7 Breast 115 25.4

Non-Hodgkin Lymphoma 35 8.3 Cervix Uteri 35 7.7

Leukemia 35 8.3 Thyroid 33 7.3

Bladder 32 7.6 Non Hodgkin Lymphoma 32 7.1

Colon 29 6.9 Leukemia 24 5.3

Stomach 27 6.4 Other skin 23 5.1

Other Skin 21 5.0 Stomach 23 5.1

Trachea,Bronchus,Lung 19 4.5 Rectum 15 3.3

Brain 16 3.8 Ovary 15 3.3

Kidney 15 3.6 Uterus 15 3.3

Table 18: Five Most Common Cancer among nationals of GCC States (1998-2007)

Oman UAE Bahrain KSA Qatar Kuwait

Male

Stomach Lung Lung Non-HodgkinLymphoma

Lung Colorectal

Non-HodgkinLymphoma

Colorectal Colorectal Colorectal ColorectalNon-HodgkinLymphoma

Leukemia Non-Hodgkin

Lymphoma

Prostate Liver Liver Lung

Prostate Prostate Bladder Leukemia Leukemia Leukemia

Lung Leukemia Leukemia Lung Bladder Prostate

Breast Breast Breast Breast Breast Breast

Thyroid Thyroid Colorectal Thyroid Thyroid Colorectal

Female Cervix Uteri Leukemia Lung Colorectal Colorectal Thyroid

Leukemia Colorectal ThyroidNon-HodgkinLymphoma

Non-HodgkinLymphoma

Non-HodgkinLymphoma

Stomach Cervix Uteri Ovary Leukemia Corpus uteri Leukemia

www.moh.gov.om 31


34/146

Overall Results

Figure 5 : The most frequent types of cancer by gender

(0-14 years)

Lymphoid L eukemias

Neuroplastoma

Acute myelo id Leukemias

Non Hodgkin Lymphoma

19.4

11.1

8.3

5.6 8.3

12.5

12.5

33.3 Lymphoid L eukemias

Hodgkin Lymphoma

Neuroplastoma

Ewing Sarcoma

Medulloblastoma

Otherremainingsites

50

5.6 4.2

29.2

Acute myelo id Leukemias

Other remaining sites

60 50 40 30 20 10 0 10 20 30 40 50 60


(15-34 years)

Leukemia


Bone

Hodgkin Lymphoma

Colon

Other remainingsites

33.3

21.6

13.7

11.8

9.8

9.8

7.9

6.8

6.8

17

27.3

34.2

Thyroid

Breast

Ovary


Leukemia

Other remaining sites

60 50 40 30 20 10 0 10 20 30 40 50 60

www.moh.gov.om 32


35/146

Overall Results


(35-54 years)

Colon 11.5 37.7 Breast

Non Hodgkin Lymphoma 10.6 9.1 Thyroid

Bladder 7.7 8.4 Cervix uteri

7.7Stomach 5.2 Non Hodgkin Lymphoma

Leukemia 5.8 3.9 StomachOther

Otherremaining 56.7 39.6 remainingsites

sites

70 50 3060 50 40 30 20 10 0 10 20 40 50 60

Figure 8 : The most frequent types of cancer by gender(55+ years)

16.8 17.6 BreastProstate

Bladder 9.9 9.6 Non Hodgkin Lymphoma

8.2 9.6Other skin Cervix uteri

7.3 8.6 StomachStomach

8 Other skin

Other

Non Hodgkin Lymphoma 6

Otherremaining 51.8 46.6 remainingsites sites

60 50 40 30 20 10 0 10 20 30 40 50 60

www.moh.gov.om 33


36/146

Overall Results

Regional DistributionThe high frequency of cancer reported from Muscat could be biased since majority of the cancer cases are

referred to the Royal hospital, Muscat and people sometimes give a local address in Muscat, rather than

giving their original place of residence.

Figure 9 : Regional Distribu tion of Incident cases, 2010(Incidence rates are per 100,000 population)

Musandam(Sultanate of Oman)

Madha(Sultanate of Oman)

Muscat

AdhDhahirah

46.3(74)

AdDakhliyah

40.6(108)

Al Wusta47.8(9)

Dhofar60.5(98)

23.1(5)

37.5(143)

56.0(225)

33.5(45)

38.6(60)

This diagram is not an authority on international boundariesData of Buraimi Governorate included in Adh Dhahirah regionThe number in the brackets is frequency.

37.6(87)

Unknown (22)www.moh.gov.om 34


37/146

35ww.moh.gov.om

Cancers by Site


38/146

Lymphoma

Lymphoma

Table 19: Gender Distr ibut ion o f Lymphomas

GenderHodgkins Lymphoma

Frequency Crudeincidence

ASRNon-Hodgkin Lymphoma

Frequency Crudeincidence

ASR

Male

Female

12

11

1.2

0.6

1.5

0.6

35

32

3.6

1.7

6

3

67Total 23

Note : Incidence per 100,000 per year

Figure 10: Age-standardized incidence rates of Hodgkin lymphoma in Oman and

some selected countries

5

2010

Figure 11: Age-standardized incidence rates of Non-Hodgkin lymphoma in Oman

and some selected countries

5

2010

Note: Data of GCC countries are from 1998-2005; data of Algeria, UK, USA and J apan are from 1993-1997; For USA-whitepopulation data was used.

www.moh.gov.om 36


39/146

Lymphoma

Figure 12: Morphology of Hodgkin Disease

UnspeciedHodgkin's disease

26%

Nodular sclerosis35%

Lymphocyticpredominace

13%

LymphocyticMixed cellularity

depletion22%

4%

Figure 13: Morphology of Non-Hodgkin lymphoma

Angioimmunoblastic T-cell lymphoma

3%

Precursor celllymphoblastic

lymphoma,NOS*

Marginal zone b-cell 4%lymphoma,NOS *

1%

Mantle cell lymphoma3%

Cutaneous T-celllymphoma,NOS*

1%

Follicular lymphoma6%

Burkittslymphoma, NOS*

7%

Mature T-celllymphoma, NOS*

1%

Malignantlymphoma, lymphoplasm

acytic1%

Anaplastic large celllymphoma

4%

Malignantlymphoma, NOS*

4%

Non- Hodgkinslymphoma, NOS*

37%

Malignantlymphoma, largeB-cell, diffuse, NOS*

28%

www.moh.gov.om 37


40/146

Hodgkin Lymphoma

Figure 14 : Incidence of Hodgkins Lymphoma by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

0.6(1) Ad

Dakhliyah3.0(8)

Al Wusta0.0(0)

Dhofar1.2(2)

0.0(0 )

0.8(3)

0.4(1)

1.5(6)

0.0(0)

0.6(1)

Source: Ministry of National Economy

Note : The map is not the authority on international boundaries

The number in the brackets is frequency

Unknown (1)

www.moh.gov.om 38


41/146

Non-Hodgkin Lymphoma

Figure 15 : Incidence of Non-Hodgkin Lymphoma by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

5.6(9) Ad

Dakhliyah2.6(7)

Al Wusta0.0(0)

Dhofar6.8(11)

0.0(0)

3.1(12)

2.2(5)

3.7(15)

1.5(2)

1.9(3)




Unknown (3)

www.moh.gov.om 39


42/146

Stomach

Stomach

Table 20: Gender Distribution of Gastric Cancer

Gender Frequency Crude Age Standardizedincidence incidence rate

Male 31 2.8 5.4

Female 24 1.2 2.3

Total 55


Figure 16 : Age-standardized incidence rates of stomach cancer in Oman and


5

(2010)


Figure 17: Morphology of Stomach CancerCarcinomaNOS*

2%

Malignant NeoplasmLymphoma, non- 5%Hodgkins, NOS*

2%

MalignantLymphoma, large

Bcell diffuse5%

SignetSignetrriingngcellcarcinoma

7%

Gastrointestinalstromal sarcoma

4%

Burkitt lymphomaNOS* Adenocarcinoma, NOS*2% 68%

Mucin-producingadenocarcinoma

5%www.moh.gov.om 40


43/146

Stomach

Figure 18 : Incidence of Cancer of the Stomach by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

1.3(2)

AdDakhliyah

3.4(9)

Al Wusta5.3(1)

Dhofar2.5(4)

4.6(1)

3.4(13)

1.3(3)

2.5(10)

3.0(4)

5.1(8)




Unknown (0)

www.moh.gov.om 41


44/146

Breast

Figure 19: Morphology of Breast Cancer in Oman

Malignantlymphoma, large B-cell

diffuse, NOS*1%

Papillary carcinoma1%

Malignant tumor, spindlecell type

1%

2%

Medullary carcinoma1%

Paget disease InOWUating ductmammary carcinoma,NOS*

1% 90%

Metaplasticcarcinoma, NOS*

1%

Lobular carcinoma2%

Carcinoma,NOS*

Figure 20: Age-standardized incidence rates of breast cancer in Oman and some

selected countries

(2010)

5


www.moh.gov.om 42


45/146

Breast

Figure 21 : Incidence of Breast Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

15.2(12) Ad

Dakhliyah9.0(12)

Al Wusta10.9(1)

Dhofar16.4(13)

9.7(1)

5.8(11)

13.1(15) 23.0

(45)

11.9(8)

6.4(5)

Source : Ministry of National Economy



Unknown (0)

www.moh.gov.om 43


46/146

Trachea, Bronchus, Lung


Table 21: Gender Distribu tion of Trachea, Bronchus and Lung Cancer


Male 20 1.9 4.2

Female 6 0.3 0.7

Total 26

Note : Incidence rates are per 100,000 per year

Figure 22 : Age-standardized incidence rates of trachea, bronchus and lung can-

cer in Oman and some selected countries

5

2010

Figure 23 : Morphology of Trachea, Bronchus and Lung Cancer

Other speciedUnspecied

carcer 4%carcer 8%

Squamous cell

carcinoma 22%

Unspecified

Small cellcarcinoma 12%

2WKHUVSHFLHG

carcinoma12%

Adenocarcinoma34%

carcinoma 8%

www.moh.gov.om 44


47/146


Figure 24 : Incidence of Trachea, Bronchus and Lung Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

0.6(1)

AdDakhliyah

0.0(0)

Al Wusta0.0(0)

Dhofar0.0(0)

4.6(1)

2.4(9)

0.9(2)

1.7(7)

1.5(2)

1.9(3)


Data of Buraimi Governorate included in Adh Dhahirah region


Unknown (1)

www.moh.gov.om 45


48/146

Urinary Bladder

Urinary Bladder

Table 22: Gender Distribu tion of Urinary Bladder Cancer


Male 32 3.3 6.7

Female 8 0.4 0.7

Total 40


Figure 25 : Age-standardized incidence rates of bladder cancer in Oman and


2010

5

5 10 15 20 25 30


Figure 26: Morphology of Urinary Bladder Cancer

Unspecified cancer

Unspecified 3%

Transitional cell

carcinoma

92%

carcinoma

5%

www.moh.gov.om 46

35


49/146

Urinary Bladder

Figure 27 : Incidence of Urinary Bladder Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

3.8(6) Ad

Dakhliyah1.5(4)

Al Wusta0.0(0)

Dhofar1.2(2)

0.0(0)

2.9(11)

2.6(6) 1.5

(6)

1.5(2)

1.3(2)

This diagram is not an authority on international boundariesData of Buraimi Governorate included in Adh Dhahirah regionThe number in the brackets is frequencyUnknown (1)

www.moh.gov.om 47


50/146

Prostate

Prostate

Figure 28 : Age-standardized incidence rates of the prostate cancer in Oman and


2010

5


Figure 29: Morphology of Prostatic Cancer

CarCarcciinomanoma NOS*

Adenocarcinoma, NOS*

72%

Neoplasm2%

Squamous cellcarcinoma NOS*

2%

Transitional cell

carcinoma5%

Papillary transitionalcell carcinoma

2%

17%

*Not otherwise specified

www.moh.gov.om 48


51/146

Prostate

Figure 30 : Incidence of Prostatic Cancer by Region(Incidence rates are per 100,000 population)

Dhofar6.0(5)

This diagram is not an authority on international boundariesData of Buraimi Governorate included in Adh Dhahirah regionThe number in the brackets is frequency



Muscat

AdhDhahirah

2.5(2) Ad

Dakhliyah4.5(6)

Al Wusta

Dhofar

6.0(5)

0.0(0)

8.9(1)

2.1(4)

5.1(6)

5.3(11)

4.5(3)

1.3(1)

Unknown (2)

www.moh.gov.om 49


52/146

Skin

Skin

Table 23 : Gender Distribution of Skin Cancer


Male 28 2.1 4.4

Female 24 1.2 2.2

Total 52

Figure 31: Age-standardized incidence rates of cancer of the skin in Oman and


5

2010

Figure 32: Morphology of Skin CancerMalignant melanoma ,NOS*

*Malignant lymphoma, large Dermato brosarcoma,NOS6%B cell,diffuse,NOS* 2% Cutaneous T cell

2% Adenocarcinoma lymphoma,NOS*2%

Malignant epithelioid Squamous cell carcinomahemangioendothelioma

Synovial sarcoma,NOS*2% 2%

Non-Hodgkin lymphoma2%

Hemangiosarcoma2%

21%2%

Malignant tumor gaint celltype2%

adinoid cystic carcinoma2%

Basal cell carcinoma

45%Carcinoma,NOS*

2%Kaposis sarcoma

6%

www.moh.gov.om 50


53/146

Skin

Figure 33 : Incidence of Skin Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

4.4(7) Ad

Dakhliyah2.3(6)

Al Wusta5.3(1)

Dhofar1.2(2)

4.6(1)

2.4(9)

2.2(5)

4.2(17)

2.2(3)

0.6(1)



The number in the brackets is the frequency

Unknown (0)

www.moh.gov.om 51


54/146

Colon

Colon

Table 24 : Gender Distribution of the Colon Cancer


Male 29 3 5.2

Female 11 0.6 0.9

Total 40

Figure 34: Age-standardized inc idence rates of the colon cancer in Oman and some

selected countries

20105


Figure 35: Morphology of Colonic Cancer

Unspecifiedcarcinoma

CarcinoidVillous

adenocarcinoma

3%

5%tumor, NOS*

3%

Adenocarcinoma, NOS*

79%

Mucinous

adenocarcinoma10%

* Not otherwise specified

www.moh.gov.om 52


55/146

Colon

Figure 36 : Incidence of the Colon Cancer by Region(Incidence rates are per 100,000 population)






Muscat

AdhDhahirah

2.5(4) Ad

Dakhliyah1.5(4)

Al Wusta0.0(0)

Dhofar3.7(6)

0.0(0)

1.0(4)

1.3(3)

2.7(11)

1.4(2)

1.9(3)

Unknown(3)

www.moh.gov.om 53


56/146

Rectum

Rectum

Table 25: Gender Distribution of the Rectum Cancer


Male 9 0.9 1.7

Female 15 0.8 1.5

Total 24


Figure 37: Age- Standardized incidence rate of the rectum cancer inOman and some selected count ries

2010

5


Figure 38 : Morphology of Rectal CancerNeoplasm Verrucous


carcinoma, NOS*

4%

Signet ring cellcarcinoma

4%

Mucinousadenocarcinoma

4%

4%

Adenocarcinoma,

NOS*70%

www.moh.gov.om 54


57/146

Rectum

Figure 39 : Incidence of Rectum Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

0.6(1)

AdDakhliyah

1.1(3)

Al Wusta0.0(0)

Dhofar1.2(2)

0.0(0)

0.3(1)

1.3(3)

1.2(5)

2.2(3)

3.2(5)




Unknown(1)

www.moh.gov.om 55


58/146

Bone

Bone

Table 26: Gender Distribution of Bone Cancer


Male 14 1.2 1.3

Female 4 0.2 0.2

Total 18


Figure 40: Age-standardized inc idence rates of bone cancer in Oman and some

selected countries

5

2010

Figure 41 : Morphology of Bone Cancer

22%

Unspecified cancer6%

Fibrosarcoma6%

Osteosarcoma28%

Ewings sarcoma38%

Other specified cancer

www.moh.gov.om 56


59/146

Bone

Figure 42 : Incidence of Bone Cancer by Region(Incidence rates are per 100,000 population)






Muscat

AdhDhahirah

0.0(0) Ad

Dakhliyah1.1(3)

Al Wusta5.3(1)

Dhofar1.9(3)

0.0(0)

1.8(7)

0.0(0)

0.2(1)

0.7(1)

0.6(1)

Unknown(1)

www.moh.gov.om 57


60/146

Thyroid

Thyroid

Table27: Gender Distribution of Thyro id Cancer


Male 2 0.2 0.4

Female 33 1.7 2.2

Total 35


Figure 43: Age-standardized inc idence rates of thyroid cancer in Oman and some

selected countries

2010

5

Figure 44 : Morphology of Thyroid Cancer

UnspeFLHGOther VSHFLed

Follicularcarcinoma

3%

UnspeFLHGcarcinoma

3%

cancer3%

carcinoma6%

Pappillarycarcinoma

85%

www.moh.gov.om 58


61/146

Thyroid

Figure 45 : Incidence of the Thyroid Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

3.1(5)

AdDakhliyah

1.1(3)

Al Wusta0.0(0)

Dhofar3.1(5)

0.0(0)

1.0(4)

0.9(2)

2.7(11)

1.5(2)

1.3(2)




Unknown(1)

www.moh.gov.om 59


62/146

Leukemia

Leukemia

Table 28: Gender Distribution of Leukemia


Male 35 3.5 4.2

Female 24 1.2 1.5

Total 59


Figure 46 : Age-standardized inc idence rates of luekemia in Oman and some

selected countries

2010

5


Figure 47 : Morphology of Leukemia Chronic lymphoidleukemia2% Acute myeloid

leukemia28%

Chronic myeloidleukemia

15%

Unspecied myeloidleukemia

UnspHFLHG leukemia7%

Acute lymphoidleukemia

15%

Other speciedlymphoid leukemia

27%

Other specied acute 3%leukemia

3%

www.moh.gov.om 60


63/146

Leukemia

Figure 48 : Incidence of Leukemia by Region(Incidence rates are per 100,000 population)




Unknown (2)



Muscat

AdhDhahirah

3.8(6) Ad

Dakhliyah2.6(7)

Al Wusta0.0(0)

Dhofar4.9

(8)

0.0(0)

2.6(10)

4.3(10)

3.2(13)

1.5(2)

0.6(1)

www.moh.gov.om 61


64/146

Brain and Nervous System


Table 29: Gender Distr ibut ion of Brain and Nervous System Cancer

*HQGHU )UHTXHQF\ &UXGH $JH6WDQGDUGL]HGLQFLGHQFH LQFLGHQFHUDWH

Male 19 1.6 2

)HPDOH 16 1

Total 35

1RWH,QFLGHQFHSHUSHU\HDU

Figure 49: Age-standardized incidence rates of cancer of the brain and nervous

system cancer in Oman and some selected countries

5

2010

Note:'DWDRI*&&FRXQWULHVDUHIURPGDWDRIAlgeria, UK, USADQG-DSDQDUHIURP)RU86$ZKLWHSRSXODWLRQGDWDZDVXVHG

Figure 50 : Morphology of Brain and Nervous System Cancer

umours o crananerves

3%

Astrocytic tumours-tumoursgliomas

36%

Soft tissue tumour3%

Meningoma6%

Other embryonal tumours6%

Gliomas of uncertainorigin6%

9% 9%

UnspecLHG tumours3%

Other VSHFLHGtumours16%

(SHQGymal tumours3%MHGXOORblastoma

2OLJRGeQGURJOLDO tumoursDQG mixHGJOLomas

www.moh.gov.om 62


65/146


Figure 51 : Incidence of Brain and Nervous System Cancer by Region

(Incidence rates are per 100,000 population)




Muscat

AdhDhahirah

1.3(2) Ad

Dakhliyah2.6(7)

Al Wusta5.3(1)

Dhofar1.9(3)

0.0(0)

1.3

(5)

0.4(1)

2.7(11)

0.7(1)

2.6(4)

Unknown(0)

www.moh.gov.om 63


66/146

Cervix

Cervix

Figure 52 : Age-standardized incidence rates of the cervix cancer in Oman and


5

2010

Note: Data of GCC countries are from 1998-2005; data of Algeria, UK, USA and J apan are from 1993-1997; For USA-white

population data was used.

Figure 53 : Morphology of the Cervix Cancer

Unspecified

cancer

3%

Squamous cell

carcinoma

63%

Adenocarcinoma,

34%

www.moh.gov.om 64


67/146

Cervix

Figure 54 : Incidence of Cervical Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

3.8(3) Ad

Dakhliyah3.8(5)

Al Wusta10.9(1)

Dhofar1.3

(1)

0.0(0)

2.6(5)

4.4(5)

5.1(10)

3.0(2)

3.9(3)

This diagram is not an authority on international boundariesData of Buraimi Governorate included in Adh Dhahirah regionThe number in the brackets is frequencyUnknown(0)

www.moh.gov.om 65


68/146

Liver

Liver

Table 30: Gender Distribution of Liver Cancer


Male 16 1.5 3.1

Female 14 0.7 1.5

Total 30


Figure 55: Age-standardized inc idence rates of the liver cancer in Oman andsome selected countries

Oman ( 2010)

5



Figure 56 : Morphology of Liver Cancer

Hepatoblastoma10%

Hepatocellularcarcinoma

70%

Cholangiocarcinoma

40%

Unspecifiedcarcinoma

3%

Other sarcoma3%

Other specifiedcarcinoma

10%

www.moh.gov.om 66


69/146

Liver

Figure 57 : Incidence of Liver Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

0.0(0) Ad

Dakhliyah1.1(3)

Al Wusta0.0(0)

Dhofar3.7(6)

0.0(0)

1.6(6)

1.7(4)

2.2(9)

0.0(0)

1.3(2)


www.moh.gov.om 67


70/146

Esophagus

Esophagus

Table 31 : Gender Distribution of Esophagus Cancer


Male 13 1.3 2.9

Female 5 0.3 0.5

Total 18


Figure 58: Age-standardized incidence rates of the esophagus cancer in Oman

and some selected countries

2010

5


Figure 59 : Morphology of Esophageal Cancer

Unspecified cancer

6%

Squamous cellcarcinoma

39%

Adenocarcinoma

55%

www.moh.gov.om 68


71/146

Esophagus

Figure 60 : Incidence of Esophageal Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

1.3(2) Ad

Dakhliyah1.1(3)

Al Wusta0.0(0)

Dhofar1.9(3)

0.0(0)

1.0(4)

0.9(2)

0.5(2)

0.0(0)

1.3(2)


www.moh.gov.om 69


72/146

Kidney and Ureter

Kidney and Ureter

Table 32: Gender Distribution of the Kidney & Ureter Cancer

Gender Frequency Crude Age Standardized

incidence incidence rate

Male 16 1.5 2.7

Female 9 0.5 0.7

Total 25


Figure 61 : Age-standardized inc idence rates of the kidney cancer in Oman and


5

2010



Figure 62 : Morphology of Kidney and Ureter Cancer

Nephroblastoma12%

Other specified cancer4%

Squamous cell carcinoma

12%

Renal cell carcinoma72%

www.moh.gov.om 70


73/146

Kidney and Ureter

Figure 63 : Incidence of Kidney and Ureter Cancer by Region(Incidence rates are per 100,000 population)




Muscat

AdhDhahirah

0.0(0) Ad

Dakhliyah2.6(7)

Al Wusta5.3(1)

Dhofar2.5(4)

0.0(0)

0.8(3)

1.3(3)

1.2(5)

0.7(1)

0.6(1)

Unknown(0)

www.moh.gov.om 71


74/146

Pancreas

Pancreas

Table 33: Gender Dist ribution of the Pancreas Cancer


Male 11 1.1 2.4

Female 3 0.2 0.3

Total 14


Figure 64: Age-standardized incidence rates of the pancreas cancer in Oman and


5

2010

1 2 3 4 5 6 7 8 9 10



Figure 65 : Morphology of Pancreatic Cancer

Neoplasm21%

Papillarycarcinoma, NOS*

7%

Adenocarcinoma, NOS*72%


www.moh.gov.om 72


75/146

Pancreas

Figure 66 : Incidence of Pancreatic Cancer by Region(Incidence rates are per 100,000 population)



Muscat

AdhDhahirah

0.0(0) Ad

Dakhliyah0.4(1)

Al Wusta0.0(0)

Dhofar2.5(4)

0.0(0)

0.3(1)

0.4(1)

0.5(2)

0.7(1)

1.3(2)


Unknown(2)www.moh.gov.om 73


76/146

Ovary

Ovary

Figure 67: Age-standardized incidence rates of the ovary cancer in Oman and


5

2010

Note: Data of GCC countries are from 1998-2005; data of Algeria, UK, USA and J apan are fro

Documents

Cancer Incidence in Oman 2010